FDA OKs implant for enlarged prostate symptoms

September 13, 2013

(AP)—Federal health regulators have approved the first permanent implant to treat men's urinary problems caused by an enlarged prostate.

The Food and Drug Administration says it approved the Urolift system to relieve low or blocked urine flow in men age 50 or older. The implant works by holding back that presses against the urethra, causing difficulty urinating.

More than half of men in their sixties have some due to enlarged prostate, including frequent urination, weak stream and leaking. Current treatment options include drug therapy and surgery to remove part of the prostate. The Urolift is implanted by a doctor using a handheld device that is inserted through the urethra.

Side effects reported in company trials include pain during urination, blood in urine and decreased urine flow.

Explore further: Shape of urine stream can indicate prostate issues

Related Stories

Recommended for you

Research holds promise for personalized lung cancer treatments

January 12, 2017

New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another. Scientists also identified ...

Tumor-seeking salmonella treats brain tumors

January 11, 2017

Biomedical engineers at Duke University have recruited an unlikely ally in the fight against the deadliest form of brain cancer—a strain of salmonella that usually causes food poisoning.

New genes identified that regulate the spread of cancers

January 11, 2017

Research led by the Wellcome Trust Sanger Institute has discovered a new biological target for drugs to reduce the spread of tumours in cancer patients. Published in Nature today, the study with genetically modified mice ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.